Localization of RANKL in osteolytic tissue around a loosened joint prosthesis

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 4, 2004, Pages 346-351

  Horiki, Mitsuru ^a   Nakase, Takanobu ^a   Myoui, Akira ^a   Sugano, Nobuhiko ^a   Nishii, Takashi ^a   Tomita, Tetsuya ^a   Miyaji, Takahiro ^a   Yoshikawa, Hideki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Loosening; RANKL; TACE

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMPLANTATION; JOINT PROSTHESIS; MACROPHAGE ACTIVATION; MEMBRANE BINDING; MONONUCLEAR CELL; MULTINUCLEAR CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS LOOSENING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 3242787387     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-003-0493-8     Document Type: Article

References (31)

1. Paterson M, Fulford P, Denham R (1986) Loosening of the femoral component after total hip replacement. The thin black line and the sinking hip. J Bone Joint Surg Br 68:392-397
2. Harris WH (1994) Osteolysis and particle disease in hip replacement. A review. Acta Orthop Scand 65:113-123
3. Atkins RM, Langkamer VG, Perry MJ, Elson CJ, Collins CM (1997) Bone-membrane interface in aseptic loosening of total joint arthroplasties. J Arthroplasty 12:461-464
4. Goodman SB, Huie P, Song Y, Schurman D, Maloney W, Woolson S, Sibley R (1998) Cellular profile and cytokine production at prosthetic interfaces. Study of tissues retrieved from revised hip and knee replacements. J Bone Joint Surg Br 80:531-539
5. Jones LC, Frondoza C, Hungerford DS (1999) Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res 48:889-898
6. Voronov I, Santerre JP, Hinek A, Callahan JW, Sandhu J, Boynton EL (1998) Macrophage phagocytosis of polyethylene particulate in vitro. J Biomed Mater Res 39:40-51
7. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179
8. Horowitz MC, Xi Y, Wilson K, Kacena MA (2001) Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12:9-18
9. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309
10. Nakase T, Kaneko M, Tomita T, Myoui A, Ariga K, Sugamoto K, Uchiyama Y, Ochi T, Yoshikawa H (2000) Immunohistochemical detection of cathepsin D, K, and L in the process of endochondral ossification in the human. Histochem Cell Biol 114:21-27
11. Ohsawa Y, Nitatori T, Higuchi S, Kominami E, Uchiyama Y (1993) Lysosomal cysteine and aspartic proteinases, acid phosphatase, and an endogenous cysteine proteinase inhibitor, cystatin-beta, in rat osteoclasts. J Histochem Cytochem 41:1075-1083
12. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729-733
13. Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen KJ, Rose-John S (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278:38829-38839
14. Neale SD, Athanasou NA (1999) Cytokine receptor profile of arthroplasty macrophages, foreign body giant cells and mature osteoclasts. Acta Orthop Scand 70:452-458
15. Jones LC, Frondoza C, Hungerford DS (1999) Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res 48:889-898
16. Sugiyama T (2001) Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Miner Metab 19:89-96
17. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, Findlay DM (2001) The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 83:902-911
18. Sabokbar A, Pocock A, Kudo O, Neale SD, Schulze E, Danks L, Athanasou NA (2001) Exression of osteoclastgenic markers in inflamed synovial tissues in prosthesis loosening and arthritis. Bone 28:S163
19. Takahashi N, Udagawa N, Suda T (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256:449-455
20. Romas E, Bakharevski O, Hards DK, Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT (2000) Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 43:821-826
21. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM (2000) Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15:640-649
22. Greenfield EM, Bi Y, Ragab AA, Goldberg VM, Van De Motter RR (2002) The role of osteoclast differentiation in aseptic loosening. J Orthop Res 20:1-8
23. Athanasou NA, Quinn J, Bulstrode CJ (1992) Resorption of bone by inflammatory cells derived from the joint capsule of hip arthroplasties. J Bone Joint Surg Br 74:57-62
24. Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28:370-377
25. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, Van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534-3540
26. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474
27. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR (2001) Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61:2572-2578
28. Simonet WS, Lacey DL, Dunstan CR, Simonet WS, Lacey DL, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
29. Ulrich-Vinther M, Carmody EE, Goater JJ, Soballe K, O'Keefe RJ, Schwarz EM (2002) Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 84:1405-1412
30. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM (2002) Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 20:169-173
31. Juji T, Hertz M, Aoki K, Horie D, Ohya K, Gautam A, Mouritsen S, Oda H, Nakamura K, Tanaka S (2002) A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. J Bone Miner Metab 20: 266-268